Kinetics of human erythrocyte acetylcholinesterase inhibition by a novel derivative of physostigmine: phenserine. 1998

A A al-Jafari, and M A Kamal, and N H Greig, and A S Alhomida, and E R Perry
Department of Biochemistry, College of Science, King Saud University, Riyadh, Saudi Arabia. JAFARI@KSU.EDU.SA

The effect of phenserine, a novel cholinesterase inhibitor, was assessed for the first time on kinetic parameters of human erythrocyte acetylcholinesterase (AChE). Phenserine (0.025-0.40 microM) inhibited the activity of human erythrocyte AChE in a concentration-dependent fashion, the IC50 was 0.0453 microM. The Michaelis-Menten constant (K(m)) for the hydrolysis of acetylthiocholine iodide was found to be 0.124 mM and the Vmax was 0.980 mumol/min/mg protein. Dixon as well as Lineweaver-Burk plots and their secondary replots indicated that the nature of the inhibition was of the noncompetitive type. The value of Ki was estimated as 0.048 microM by the primary and secondary replots of the Dixon as well as secondary replots of the Lineweaver-Burk plot. A novel relationship between Ki and substrate concentration was also identified which permits more precise prediction of the specific type of noncompetitive inhibition of various enzymes by a wide variety of drugs, chemicals and, in some circumstances, by their own substrates.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D010830 Physostigmine A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity. Eserine
D002800 Cholinesterase Inhibitors Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system. Acetylcholinesterase Inhibitor,Acetylcholinesterase Inhibitors,Anti-Cholinesterase,Anticholinesterase,Anticholinesterase Agent,Anticholinesterase Agents,Anticholinesterase Drug,Cholinesterase Inhibitor,Anti-Cholinesterases,Anticholinesterase Drugs,Anticholinesterases,Cholinesterase Inhibitors, Irreversible,Cholinesterase Inhibitors, Reversible,Agent, Anticholinesterase,Agents, Anticholinesterase,Anti Cholinesterase,Anti Cholinesterases,Drug, Anticholinesterase,Drugs, Anticholinesterase,Inhibitor, Acetylcholinesterase,Inhibitor, Cholinesterase,Inhibitors, Acetylcholinesterase,Inhibitors, Cholinesterase,Inhibitors, Irreversible Cholinesterase,Inhibitors, Reversible Cholinesterase,Irreversible Cholinesterase Inhibitors,Reversible Cholinesterase Inhibitors
D004912 Erythrocytes Red blood cells. Mature erythrocytes are non-nucleated, biconcave disks containing HEMOGLOBIN whose function is to transport OXYGEN. Blood Cells, Red,Blood Corpuscles, Red,Red Blood Cells,Red Blood Corpuscles,Blood Cell, Red,Blood Corpuscle, Red,Erythrocyte,Red Blood Cell,Red Blood Corpuscle
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000110 Acetylcholinesterase An enzyme that catalyzes the hydrolysis of ACETYLCHOLINE to CHOLINE and acetate. In the CNS, this enzyme plays a role in the function of peripheral neuromuscular junctions. EC 3.1.1.7. Acetylcholine Hydrolase,Acetylthiocholinesterase,Hydrolase, Acetylcholine
D000122 Acetylthiocholine An agent used as a substrate in assays for cholinesterases, especially to discriminate among enzyme types. (2-Mercaptoethyl)trimethylammonium Acetate

Related Publications

A A al-Jafari, and M A Kamal, and N H Greig, and A S Alhomida, and E R Perry
January 1997, Anticancer research,
A A al-Jafari, and M A Kamal, and N H Greig, and A S Alhomida, and E R Perry
September 1995, The international journal of biochemistry & cell biology,
A A al-Jafari, and M A Kamal, and N H Greig, and A S Alhomida, and E R Perry
June 1976, Research communications in chemical pathology and pharmacology,
A A al-Jafari, and M A Kamal, and N H Greig, and A S Alhomida, and E R Perry
September 1991, The Biochemical journal,
A A al-Jafari, and M A Kamal, and N H Greig, and A S Alhomida, and E R Perry
January 1988, Biomedica biochimica acta,
A A al-Jafari, and M A Kamal, and N H Greig, and A S Alhomida, and E R Perry
January 1966, Biochemistry,
A A al-Jafari, and M A Kamal, and N H Greig, and A S Alhomida, and E R Perry
June 2007, Molecular pharmacology,
A A al-Jafari, and M A Kamal, and N H Greig, and A S Alhomida, and E R Perry
January 1990, Drug and chemical toxicology,
A A al-Jafari, and M A Kamal, and N H Greig, and A S Alhomida, and E R Perry
August 1991, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies,
A A al-Jafari, and M A Kamal, and N H Greig, and A S Alhomida, and E R Perry
October 1966, Science (New York, N.Y.),
Copied contents to your clipboard!